ANI Total Revenue vs Extraordinary Items Analysis
ANIP Stock | USD 61.43 2.34 3.67% |
ANI Pharmaceuticals financial indicator trend analysis is way more than just evaluating ANI Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ANI Pharmaceuticals is a good investment. Please check the relationship between ANI Pharmaceuticals Total Revenue and its Extraordinary Items accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.
Total Revenue vs Extraordinary Items
Total Revenue vs Extraordinary Items Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ANI Pharmaceuticals Total Revenue account and Extraordinary Items. At this time, the significance of the direction appears to have strong relationship.
The correlation between ANI Pharmaceuticals' Total Revenue and Extraordinary Items is 0.76. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Extraordinary Items in the same time period over historical financial statements of ANI Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ANI Pharmaceuticals' Total Revenue and Extraordinary Items is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of ANI Pharmaceuticals are associated (or correlated) with its Extraordinary Items. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Extraordinary Items has no effect on the direction of Total Revenue i.e., ANI Pharmaceuticals' Total Revenue and Extraordinary Items go up and down completely randomly.
Correlation Coefficient | 0.76 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Total Revenue
Total revenue comprises all receipts ANI Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Extraordinary Items
Most indicators from ANI Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.As of 05/18/2024, Selling General Administrative is likely to grow to about 157.9 M, while Discontinued Operations is likely to drop slightly above 156 K.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 115.5M | 177.6M | 245.5M | 257.8M | Total Revenue | 216.1M | 316.4M | 486.8M | 511.2M |
ANI Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
ANI Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ANI Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 456.8M | 461.2M | 771.6M | 760.1M | 904.4M | 949.6M | |
Other Current Liab | 36.7M | 54.0M | 63.6M | 69.3M | 99.8M | 104.8M | |
Total Current Liabilities | 61.7M | 78.6M | 87.5M | 99.4M | 145.5M | 152.8M | |
Total Stockholder Equity | 212.8M | 195.7M | 358.7M | 338.5M | 432.7M | 454.4M | |
Property Plant And Equipment Net | 40.6M | 41.3M | 52.7M | 43.2M | 44.6M | 46.8M | |
Net Debt | 123.4M | 177.8M | 187.1M | 238.3M | 94.2M | 98.9M | |
Retained Earnings | 17.6M | (5.0M) | (47.8M) | (97.3M) | (80.1M) | (84.1M) | |
Accounts Payable | 14.6M | 11.3M | 23.0M | 29.3M | 36.7M | 38.5M | |
Cash | 62.3M | 7.9M | 100.3M | 48.2M | 221.1M | 232.2M | |
Non Current Assets Total | 269.1M | 290.9M | 449.8M | 415.8M | 384.8M | 404.0M | |
Cash And Short Term Investments | 62.3M | 7.9M | 100.3M | 48.2M | 221.1M | 232.2M | |
Common Stock Shares Outstanding | 12.0M | 12.0M | 12.6M | 16.3M | 18.2M | 19.1M | |
Liabilities And Stockholders Equity | 456.8M | 461.2M | 771.6M | 760.1M | 904.4M | 949.6M | |
Other Current Assets | 5.1M | 5.9M | 11.3M | 8.4M | 25.2M | 26.5M | |
Total Liab | 244.0M | 265.5M | 412.9M | 421.5M | 471.7M | 495.3M | |
Property Plant And Equipment Gross | 40.6M | 41.3M | 75.6M | 76.0M | 77.5M | 81.4M | |
Total Current Assets | 187.7M | 170.3M | 321.8M | 344.3M | 519.6M | 545.6M | |
Other Stockholder Equity | 200.1M | 212.1M | 384.7M | 398.8M | 479.2M | 503.1M | |
Accumulated Other Comprehensive Income | (4.9M) | (11.4M) | (3.1M) | 12.2M | 8.9M | 9.3M | |
Short Long Term Debt Total | 185.7M | 185.7M | 287.4M | 286.5M | 315.3M | 331.1M | |
Short Term Debt | 115.7M | 9.9M | 13.2M | 850K | 977.5K | 928.6K | |
Current Deferred Revenue | 451K | 80K | 87K | 8.2M | 9.4M | 9.9M | |
Non Currrent Assets Other | 1.2M | 802K | 2.2M | 2.6M | 6.1M | 6.4M | |
Non Current Liabilities Total | 182.3M | 186.9M | 325.3M | 322.1M | 326.2M | 342.5M | |
Net Receivables | 72.1M | 95.8M | 128.5M | 165.4M | 162.1M | 170.2M | |
Net Tangible Assets | 28.8M | 3.6M | 36.7M | 58.7M | 52.8M | 55.5M | |
Other Assets | 44.6M | 57.5M | 75.1M | 92.7M | 106.6M | 112.0M | |
Long Term Debt | 175.8M | 172.4M | 286.5M | 285.7M | 284.8M | 149.2M | |
Retained Earnings Total Equity | 17.6M | (5.0M) | (47.8M) | (97.3M) | (111.9M) | (117.5M) | |
Inventory | 48.2M | 60.8M | 81.7M | 105.4M | 111.2M | 116.8M | |
Deferred Long Term Liab | 1.5M | 800K | 500K | 600K | 690K | 458.1K | |
Intangible Assets | 180.4M | 188.5M | 294.1M | 251.6M | 209.0M | 156.5M | |
Property Plant Equipment | 40.6M | 41.3M | 52.7M | 43.2M | 49.7M | 52.2M | |
Capital Surpluse | 200.8M | 214.4M | 387.8M | 403.9M | 464.5M | 237.5M | |
Other Liab | 7K | 201K | 31.0M | 35.1M | 40.3M | 42.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for ANI Stock analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 13.824 | Earnings Share 1.61 | Revenue Per Share 27.705 | Quarterly Revenue Growth 0.287 | Return On Assets 0.0391 |
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.